197 related articles for article (PubMed ID: 23843637)
1. Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.
Murata T; Narita Y; Sugimoto A; Kawashima D; Kanda T; Tsurumi T
J Virol; 2013 Sep; 87(18):10148-62. PubMed ID: 23843637
[TBL] [Abstract][Full Text] [Related]
2. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.
Wille CK; Nawandar DM; Panfil AR; Ko MM; Hagemeier SR; Kenney SC
J Virol; 2013 Jan; 87(2):935-50. PubMed ID: 23135711
[TBL] [Abstract][Full Text] [Related]
3. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
4. Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins.
Li L; Su X; Choi GC; Cao Y; Ambinder RF; Tao Q
BMC Cancer; 2012 Mar; 12():125. PubMed ID: 22458933
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
Jung YJ; Choi H; Kim H; Lee SK
J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
7. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein.
Murata T; Sato Y; Nakayama S; Kudoh A; Iwahori S; Isomura H; Tajima M; Hishiki T; Ohshima T; Hijikata M; Shimotohno K; Tsurumi T
J Biol Chem; 2009 Mar; 284(12):8033-41. PubMed ID: 19164291
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Epstein-Barr virus reactivation from latency.
Murata T
Microbiol Immunol; 2014 Jun; 58(6):307-17. PubMed ID: 24786491
[TBL] [Abstract][Full Text] [Related]
9. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
10. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
Siddiqi UZ; Vaidya AS; Li X; Marcon E; Tsao SW; Greenblatt J; Frappier L
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341047
[TBL] [Abstract][Full Text] [Related]
11. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency.
McDonald C; Karstegl CE; Kellam P; Farrell PJ
J Gen Virol; 2010 Mar; 91(Pt 3):622-9. PubMed ID: 19923262
[TBL] [Abstract][Full Text] [Related]
13. Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency.
Robinson AR; Kwek SS; Hagemeier SR; Wille CK; Kenney SC
J Virol; 2011 Sep; 85(17):8940-53. PubMed ID: 21697476
[TBL] [Abstract][Full Text] [Related]
14. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
Yu X; McCarthy PJ; Wang Z; Gorlen DA; Mertz JE
J Virol; 2012 Aug; 86(15):8086-96. PubMed ID: 22623769
[TBL] [Abstract][Full Text] [Related]
15. Switching of EBV cycles between latent and lytic states.
Murata T; Tsurumi T
Rev Med Virol; 2014 May; 24(3):142-53. PubMed ID: 24339346
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T
J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272
[TBL] [Abstract][Full Text] [Related]
17. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
Kim JY; Min YJ; Lee M-H; An YR; Ashktorab H; Smoot DT; Kwon SW; Lee SK
J Virol; 2024 Feb; 98(2):e0177623. PubMed ID: 38197630
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter.
Sun CC; Thorley-Lawson DA
J Virol; 2007 Dec; 81(24):13566-77. PubMed ID: 17898050
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency.
Murata T; Noda C; Saito S; Kawashima D; Sugimoto A; Isomura H; Kanda T; Yokoyama KK; Tsurumi T
J Biol Chem; 2011 Jun; 286(25):22007-16. PubMed ID: 21525011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
